Nowadays, combination therapy is the major tumor therapy approach, and a recent study found that an anti PD-1 drug (atezolizumab) combined with an anti-vascular endothelial growth factor drug (bevacizumab) led to encouraging antitumor activity and safety in patients with unresectable HCC (Finn et al., 2020). Here, VEGFA is linked to hepatocellular carcinoma.